Novo Nordisk reported in the press release that the 1-year extension period in the evoke and evoke+ trials will be discontinued based on the efficacy results observed in the overall study population. Further details about the topline results were presented yesterday at the Clinical Trials on Alzheimer's Disease Conference in San Diego, CA, and Novo Nordisk said in the news release that full results will be presented at the Alzheimers and Parkinsons Diseases Conferences in March 2026
Novo Nordisk dropped its lawsuit against the telehealth provider, Hims & Hers, on Monday
Ultimately, the integrity of your research is a chain, and reconstitution is one of its most critical links
doi: 10.1016/S0167-0115(03)00120-4 [DOI] [PMC free article] [PubMed] [Google Scholar] 20.Gault VA, Flatt PR, Harriott P, Mooney MH, Bailey CJ, OHarte FP
Research shows that ongoing GLP-1 receptor stimulation quickly leads to tachyphylaxis of gastric emptying effects [24]